When compared with serum visfatin levels <0.51 ng/mL (Table 2), HCC risk was significantly increased for 0.51-0.89 ng/mL levels (OR=5.34, 95CI%=2.050-13.894), 0.891-1.454 ng/mL levels (OR=4.90, 95CI%=1.914-12.526), and ≥1.455 ng/mL levels (OR=6.69, 95CI%=2.648-16.879), indicating there was a high HCC risk in CHB and LC patients with elevated serum visfatin levels. The gene discussed is NAMPT; the disease is hepatocellular carcinoma.